Abstract 154P
Background
Apatinib, a novel treatment option for chemotherapy-refractory advanced gastric cancer (AGC), has not yet been evaluated in patients with locally AGC. This trial investigated the efficacy and safety of apatinib combined with S-1 plus oxaliplatin (SOX) as a neoadjuvant treatment for locally AGC.
Methods
Patients with M0 and either T2-T4 or N+ disease received apatinib (500 mg orally once daily on days 1-21 and discontinued in the last cycle) plus SOX (S-1, 40-60 mg orally twice daily on days 1-14; oxaliplatin, 130 mg/m2 intravenously on day 1) given every 3 weeks for 2-5 cycles. D2 gastrectomy was performed 2-4 weeks after the last cycle. To further compare the efficacy and safety between apatinib plus SOX (ASOX group) and SOX alone (SOX group), we reviewed historical control patients receiving SOX as neoadjuvant chemotherapy at the central center. The primary end point was the R0 resection rate.
Results
Between July 2017 and June 2019, 48 and 58 patients were enrolled in the ASOX and SOX groups, respectively. Forty patients in the ASOX group (83.3%) and 47 patients in the SOX group (81.0%) underwent surgery, with R0 resection rates of 75.0% and 67.2%, respectively (P=0.382). The proportion of patients with T downstaging in the ASOX group was significantly higher than that in the SOX group (36.4% vs 18.5%, P=0.036). For patients with target lesions, the radiological response rate was significantly higher in the ASOX group (75.0% vs 38.5%, P=0.015). Moreover, the ASOX group was associated with significantly higher proportions of patients achieving major pathological response (25.0% vs 10.3%, P=0.046). Grade 3 toxicities occurred in 33.3% of the ASOX patients, and no grade 4 toxicities or drug-related deaths were observed.
Conclusions
Apatinib combined with SOX showed promising efficacy with an acceptable safety profile as the first-line neoadjuvant treatment for locally AGC.
Clinical trial identification
NCT03192735.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Lymph nodes metastasis is the most important factor associated with pattern of recurrence following curative resection of gastric adenocarcinoma
Presenter: Fu-Hai Wang
Session: e-Poster Display Session
144P - Clinical implication of DNA damage response gene in patients with stage II or III gastric cancer
Presenter: In Gyu Hwang
Session: e-Poster Display Session
145P - A nomogram for predicting the benefit of adjuvant chemotherapy after resection in patients with Borrmann type IV gastric cancer
Presenter: Qing-Zhu Qiu
Session: e-Poster Display Session
146P - Red cell distribution width and mean corpuscular volume ratio as a promising new marker for chemotherapy effects in remnant gastric cancer: An analysis of a multi-institutional database
Presenter: Kai-Xiang Xu
Session: e-Poster Display Session
147P - Can the clinical stage of the 8th edition of the Union for International Cancer Control TNM classification stratify prognosis of patients with Siewert type II/III cancer?
Presenter: Hayato Watanabe
Session: e-Poster Display Session
148P - MCV-the ideal answer to predict the prognosis of remnant gastric cancer: An analysis from a multi-institutional database
Presenter: Kai Weng
Session: e-Poster Display Session
149P - Molecular and clinical characteristics of patients with resectable gastric cancer
Presenter: Zhi Zheng
Session: e-Poster Display Session
150P - Real-world assessment of the treatment patterns associated with unresectable advanced and metastatic gastric cancer in China
Presenter: Xiao Sun
Session: e-Poster Display Session
151P - Treatment patterns, healthcare resource use, economic and survival outcomes associated with unresectable advanced metastatic gastric cancers in Taiwan
Presenter: Chee Jen Chang
Session: e-Poster Display Session
152P - ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBV-encoded miRNAs, but not by DNA promotor hypermethylation
Presenter: Koji Kase
Session: e-Poster Display Session